3951
Periodic Acid Solution
1 g/dL in deionized water
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
form
solution
Quality Level
shelf life
expiry date on label
reaction suitability
reagent type: oxidant
IVD
for in vitro diagnostic use
concentration
1 g/dL in deionized water
pH
1.77
application(s)
hematology
histology
shipped in
wet ice
storage temp.
2-8°C
SMILES string
OI(O)(O)(O)(O)=O
InChI
1S/H5IO6/c2-1(3,4,5,6)7/h(H5,2,3,4,5,6,7)
InChI key
TWLXDPFBEPBAQB-UHFFFAOYSA-N
Application
For use in procedure no. 395 for Periodic Acid-Schiff (PAS) and Silver Stain Procedure No. HT100.
Still not finding the right product?
Explore all of our products under Periodic Acid Solution
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 3 - Eye Dam. 1 - Skin Corr. 1
Storage Class
8B - Non-combustible corrosive hazardous materials
wgk
WGK 2
ppe
Faceshields, Gloves, Goggles, type ABEK (EN14387) respirator filter
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Allison M Bradbury et al.
Journal of neuroscience research, 94(11), 1007-1017 (2016-09-18)
Globoid cell leukodystrophy (GLD), or Krabbe's disease, is a debilitating and always fatal pediatric neurodegenerative disease caused by a mutation in the gene encoding the hydrolytic enzyme galactosylceramidase (GALC). In the absence of GALC, progressive loss of myelin and accumulation
Robert W Morton et al.
The Journal of physiology, 597(17), 4601-4613 (2019-07-12)
Performing resistance exercise with heavier loads is often proposed to be necessary for the recruitment of larger motor units and activation of type II muscle fibres, leading to type II fibre hypertrophy. Indirect measures [surface electromyography (EMG)] have been used
Allison M Bradbury et al.
Human gene therapy, 29(7), 785-801 (2018-01-11)
Globoid cell leukodystrophy (GLD), or Krabbe disease, is an inherited, neurologic disorder that results from deficiency of a lysosomal enzyme, galactosylceramidase. Most commonly, deficits of galactosylceramidase result in widespread central and peripheral nervous system demyelination and death in affected infants